Next Article in Journal
Heat Shock Proteins as a Potential Therapeutic Target in the Treatment of Gestational Diabetes Mellitus: What We Know so Far
Next Article in Special Issue
Atomistic Analysis of ToxN and ToxI Complex Unbinding Mechanism
Previous Article in Journal
Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia
Previous Article in Special Issue
A Hybrid Cuckoo Search and Differential Evolution Approach to Protein–Ligand Docking
Open AccessArticle

Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking

Department of Bio and Brain engineering, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, Korea
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(10), 3204; https://doi.org/10.3390/ijms19103204
Received: 19 September 2018 / Revised: 10 October 2018 / Accepted: 15 October 2018 / Published: 17 October 2018
Recently, anoctamin1 (ANO1), a calcium-activated chloride channel, has been considered an important drug target, due to its involvement in various physiological functions, as well as its possibility for treatment of cancer, pain, diarrhea, hypertension, and asthma. Although several ANO1 inhibitors have been discovered by high-throughput screening, a discovery of new ANO1 inhibitors is still in the early phase, in terms of their potency and specificity. Moreover, there is no computational model to be able to identify a novel lead candidate of ANO1 inhibitor. Therefore, three-dimensional quantitative structure-activity relationship (3D-QSAR) pharmacophore modeling approach was employed for identifying the essential chemical features to be required in the inhibition of ANO1. The pharmacophore hypothesis 2 (Hypo2) was selected as the best model based on the highest correlation coefficient of prediction on the test set (0.909). Hypo2 comprised a hydrogen bond acceptor, a hydrogen bond donor, a hydrophobic, and a ring aromatic feature with good statistics of the total cost (73.604), the correlation coefficient of the training set (0.969), and the root-mean-square deviation (RMSD) value (0.946). Hypo2 was well assessed by the test set, Fischer randomization, and leave-one-out methods. Virtual screening of the ZINC database with Hypo2 retrieved the 580 drug-like candidates with good potency and ADMET properties. Finally, two compounds were selected as novel lead candidates of ANO1 inhibitor, based on the molecular docking score and the interaction analysis. In this study, the best pharmacophore model, Hypo2, with notable predictive ability was successfully generated, and two potential leads of ANO1 inhibitors were identified. We believe that these compounds and the 3D-QSAR pharmacophore model could contribute to discovering novel and potent ANO1 inhibitors in the future. View Full-Text
Keywords: anoctamin1 (ANO1); pharmacophore; three-dimensional quantitative structure-activity relationship (3D-QSAR); molecular docking; virtual screening anoctamin1 (ANO1); pharmacophore; three-dimensional quantitative structure-activity relationship (3D-QSAR); molecular docking; virtual screening
Show Figures

Graphical abstract

MDPI and ACS Style

Lee, Y.H.; Yi, G.-S. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking. Int. J. Mol. Sci. 2018, 19, 3204.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop